The Next Generation Genome Editing Market Size is predicted to develop with a CAGR of 21.8% during the forecast period for 2024-2031.
The Next Generation Genome Editing market is rapidly advancing with technologies that enhance the capabilities of CRISPR-Cas9, addressing its limitations and expanding its potential. These advancements provide improved precision, efficiency, and the ability to make large-scale DNA modifications. Key innovations include Bridge RNA, which facilitates large-scale insertions and rearrangements, and engineered Cas9 variants that enhance activity, broaden target ranges, and reduce immunogenicity.
The applications of these next-generation tools span various fields, including basic and clinical research for studying diseases like sickle cell and cancer, therapeutics for genetic and viral conditions, agriculture for developing resilient crops, and environmental applications for remediation and conservation. The market's growth is driven by the pursuit of more refined and versatile genetic engineering tools, as researchers seek to overcome the limitations of existing technologies, such as off-target effects and scalability challenges.
The next generation genome editing market is segmented by type of gene editing technique, application area, type of end user. By type of gene editing technique, the market is segmented recombinase-based editing, prime genome editing, bridge editing, base editing, retron library recombineering (RLR), transposon-based systems, homology-directed repair (HDR), and other emerging technologies. By application area market is categorized into drug discovery and development, diagnostics. By type of end user, the market is categorized into biotechnology companies, academic institutions, government laboratories, contract research organizations.
Base editing is significantly driving the Next Generation Genome Editing market due to its precision and safety advantages over traditional gene editing methods. This innovative technique allows for targeted alterations of single nucleotide bases in the DNA sequence without creating double-stranded breaks, which are common in other CRISPR-based methods. Ongoing advancements in base editing technologies, such as the development of modular systems for multiplex editing, are enhancing its applicability across fields like oncology, cardiology, and regenerative medicine. Companies are actively investing in base editing platforms to optimize research capabilities and therapeutic outcomes, which is expected to fuel market growth.
The Drug Discovery and Development segment within the Next Generation Genome Editing market is growing rapidly due to technological advancements, increased investment, and the rise of personalized medicine. CRISPR's simplicity and cost-effectiveness have revolutionized drug discovery by allowing efficient, targeted edits, accelerating the identification of drug targets and development of new therapies. Significant funding from public and private sectors supports research for novel treatments of genetic disorders and complex diseases. The segment also benefits from numerous clinical trials and the shift towards personalized medicine, enabling tailored therapies for individual genetic mutations, especially in oncology and rare genetic disorders.
North America's next generation genome editing market is boosted by a strong research infrastructure, high investment levels, and the presence of major industry players. The region's robust research ecosystem, comprising leading academic institutions and organizations, supports extensive R&D in genome editing, driving innovation and commercialization. Significant public and private investments, including government funding from agencies like the NIH, advance genome editing projects. Additionally, leading companies such as CRISPR Therapeutics, and Editas Medicine are at the forefront of developing and commercializing innovative CRISPR-based technologies, which are widely adopted in drug discovery and development.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 21.8 % from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type of Gene Editing Technique, Application Area, Type of End User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Addgene, Beam Therapeutics, Bio Palette Co., Ltd, Caribou Biosciences, Cellectis, Creative Biogene, CRISPR Therapeutics, Danaher Corporation, EdiGene, Inc., Editas Medicine, ElevateBio, GenKOre, GenScript, Horizon Discovery Ltd., Inscripta, Inc, Integrated DNA Technologies (IDT), Intellia Therapeutics, KromaTiD, Inc, Maravai LifeSciences, Merck KGaA, Pairwise, Precision BioSciences, ProQR Therapeutics, QI-Biodesign, Recombinetics, Revvity, Sangamo Therapeutics, Inc., Scribe Therapeutics, Shape TX, Synthego, Synthorx (part of Sanofi) |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Next Generation Genome Editing Market by Type of Gene Editing Technique -
Next Generation Genome Editing Market by Application Area -
Next Generation Genome Editing Market by Type of End User -
Next Generation Genome Editing Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.